Cargando…

The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor

Malignant perivascular epithelioid cell tumor (malignant PEComa) is a rare disease for which the diagnostic criteria and treatment options have not been established. Since PEComa is associated with upregulation of mammalian target of rapamycin (mTOR) pathway which controls Glut-1 (glucose transporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Lu, Sun, Xiaorong, Li, Yuhui, Xing, Ligang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525788/
https://www.ncbi.nlm.nih.gov/pubmed/26257526
http://dx.doi.org/10.2147/OTT.S85444
_version_ 1782384363296522240
author Sun, Lu
Sun, Xiaorong
Li, Yuhui
Xing, Ligang
author_facet Sun, Lu
Sun, Xiaorong
Li, Yuhui
Xing, Ligang
author_sort Sun, Lu
collection PubMed
description Malignant perivascular epithelioid cell tumor (malignant PEComa) is a rare disease for which the diagnostic criteria and treatment options have not been established. Since PEComa is associated with upregulation of mammalian target of rapamycin (mTOR) pathway which controls Glut-1 (glucose transporter) function, increased (18)F-fluorodeoxyglucose ((18)F-FDG) uptake may indicate the over activation of mTOR pathway and may guide selectively inhibiting mTOR pathway treatment. We report a malignant PEComa patient who presented for (18)F-FDG positron emission tomography/computed tomography (PET/CT) restaging. The tumor had shown significant avidity on PET/CT as well as an evident response to sirolimus (rapamycin, Rapamune™) that supports the utility of mTOR inhibitors as an effective treatment for malignant PEComa. Therefore, (18)F-FDG PET/CT is helpful in restaging and guiding treatment for malignant PEComa with mTOR inhibitors.
format Online
Article
Text
id pubmed-4525788
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45257882015-08-07 The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor Sun, Lu Sun, Xiaorong Li, Yuhui Xing, Ligang Onco Targets Ther Case Report Malignant perivascular epithelioid cell tumor (malignant PEComa) is a rare disease for which the diagnostic criteria and treatment options have not been established. Since PEComa is associated with upregulation of mammalian target of rapamycin (mTOR) pathway which controls Glut-1 (glucose transporter) function, increased (18)F-fluorodeoxyglucose ((18)F-FDG) uptake may indicate the over activation of mTOR pathway and may guide selectively inhibiting mTOR pathway treatment. We report a malignant PEComa patient who presented for (18)F-FDG positron emission tomography/computed tomography (PET/CT) restaging. The tumor had shown significant avidity on PET/CT as well as an evident response to sirolimus (rapamycin, Rapamune™) that supports the utility of mTOR inhibitors as an effective treatment for malignant PEComa. Therefore, (18)F-FDG PET/CT is helpful in restaging and guiding treatment for malignant PEComa with mTOR inhibitors. Dove Medical Press 2015-07-30 /pmc/articles/PMC4525788/ /pubmed/26257526 http://dx.doi.org/10.2147/OTT.S85444 Text en © 2015 Sun et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Sun, Lu
Sun, Xiaorong
Li, Yuhui
Xing, Ligang
The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor
title The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor
title_full The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor
title_fullStr The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor
title_full_unstemmed The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor
title_short The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor
title_sort role of (18)f-fdg pet/ct imaging in patient with malignant pecoma treated with mtor inhibitor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525788/
https://www.ncbi.nlm.nih.gov/pubmed/26257526
http://dx.doi.org/10.2147/OTT.S85444
work_keys_str_mv AT sunlu theroleof18ffdgpetctimaginginpatientwithmalignantpecomatreatedwithmtorinhibitor
AT sunxiaorong theroleof18ffdgpetctimaginginpatientwithmalignantpecomatreatedwithmtorinhibitor
AT liyuhui theroleof18ffdgpetctimaginginpatientwithmalignantpecomatreatedwithmtorinhibitor
AT xingligang theroleof18ffdgpetctimaginginpatientwithmalignantpecomatreatedwithmtorinhibitor
AT sunlu roleof18ffdgpetctimaginginpatientwithmalignantpecomatreatedwithmtorinhibitor
AT sunxiaorong roleof18ffdgpetctimaginginpatientwithmalignantpecomatreatedwithmtorinhibitor
AT liyuhui roleof18ffdgpetctimaginginpatientwithmalignantpecomatreatedwithmtorinhibitor
AT xingligang roleof18ffdgpetctimaginginpatientwithmalignantpecomatreatedwithmtorinhibitor